Goutham Narla
Chief Scientific Officer RAPPTA Therapeutics
Seminars
Wednesday 28th January 2026
Discovery of SW-3431, a First-in-Class Molecular Glue Activator with Potent & Selective Anti-Tumor Activity in PPP2R1A Mutant Cancers
9:00 am
- Targeting a tumor suppressor with small molecule glues to reactivate PP2A in cancer
- Mechanistic and structural insights into PP2A holoenzyme stabilization and downstream signaling effects
- Translational potential and development challenges, including chemistry optimization and preclinical efficacy
